S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Modern Day Options Trading For Beginners! (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Modern Day Options Trading For Beginners! (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Modern Day Options Trading For Beginners! (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Modern Day Options Trading For Beginners! (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Modern Day Options Trading For Beginners! (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Modern Day Options Trading For Beginners! (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Modern Day Options Trading For Beginners! (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Modern Day Options Trading For Beginners! (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Modern Day Options Trading For Beginners! (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Why Wall Street Loves These 3 Penny Stocks
Modern Day Options Trading For Beginners! (Ad)pixel
3 Leading Dividend Stocks Expected To Grow Earnings
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Modern Day Options Trading For Beginners! (Ad)pixel
Closing prices for crude oil, gold and other commodities
Low Volume Bunge Plunge Presents an Opportunity
Modern Day Options Trading For Beginners! (Ad)pixel
KB Home Strong Results Lift Prices
Carvana May Be Able To Reach Profitability This Year
NASDAQ:HALO

Halozyme Therapeutics - HALO News Today

$33.68
+0.82 (+2.50%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$32.86
$33.85
50-Day Range
$32.86
$53.28
52-Week Range
$32.83
$59.46
Volume
2.35 million shs
Average Volume
1.56 million shs
Market Capitalization
$4.56 billion
P/E Ratio
23.23
Dividend Yield
N/A
Price Target
$56.13
Get Halozyme Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.


HALO Media Mentions By Week

HALO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

HALO
News Sentiment

0.08

0.35

Average
Medical
News Sentiment

HALO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

HALO Articles
This Week

17

3

HALO Articles
Average Week

SourceHeadline
marketbeat.com logoFirst Hawaiian Bank Has $1.55 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
marketbeat.com - March 22 at 5:52 AM
marketbeat.com logoTitleist Asset Management LTD. Invests $273,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
marketbeat.com - March 21 at 7:49 AM
marketbeat.com logoHalozyme Therapeutics, Inc. Forecasted to Post Q3 2023 Earnings of $0.66 Per Share (NASDAQ:HALO)
marketbeat.com - March 20 at 1:46 AM
finance.yahoo.com logoHalozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - March 23 at 5:54 PM
MarketBeat logoHalozyme Therapeutics, Inc. to Post Q3 2023 Earnings of $0.66 Per Share, SVB Leerink Forecasts (NASDAQ:HALO)
americanbankingnews.com - March 22 at 1:54 AM
finance.yahoo.com logoStrength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?
finance.yahoo.com - March 21 at 7:53 AM
MarketBeat logoHalozyme Therapeutics (NASDAQ:HALO) Sets New 1-Year Low Following Analyst Downgrade
americanbankingnews.com - March 19 at 1:24 AM
benzinga.com logoSVB Leerink Downgrades Halozyme Therapeutics to Market Perform, Announces $42 Price Target
benzinga.com - March 18 at 8:51 PM
MarketBeat logoHalozyme Therapeutics, Inc. Forecasted to Post Q4 2023 Earnings of $0.78 Per Share (NASDAQ:HALO)
americanbankingnews.com - March 17 at 7:36 AM
MarketBeat logoHalozyme Therapeutics' (HALO) Market Perform Rating Reaffirmed at SVB Leerink
americanbankingnews.com - March 17 at 6:46 AM
msn.com logoSVB Leerink Downgrades Halozyme Therapeutics (HALO)
msn.com - March 16 at 7:31 PM
msn.com logoThe Latest Analyst Ratings for Halozyme Therapeutics
msn.com - March 16 at 2:31 PM
finance.yahoo.com logoDow Jones Rises Even As Fed's Pivot Remains Uncertain; Health Care Stocks Fall On New Medicare Plan
finance.yahoo.com - March 16 at 2:31 PM
marketwatch.com logoGlobal Hyaluronidase Market Size by Application (Dermatology, Plastic Surgery) Forecast from 2023 to 2028
marketwatch.com - March 15 at 1:54 PM
msn.com logoHalozyme sees no impact on royalties after EU body revokes J&J's Darzalex patent
msn.com - March 15 at 1:54 PM
finance.yahoo.com logoHALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
finance.yahoo.com - March 15 at 8:53 AM
MarketBeat logoHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Brokerages
americanbankingnews.com - March 15 at 3:48 AM
benzinga.com logoHalozyme Therapeutics Stock (NASDAQ:HALO), Guidance and Forecast
benzinga.com - March 14 at 5:38 AM
benzinga.com logoHalozyme Therapeutics Stock (NASDAQ:HALO), Analyst Ratings, Price Targets, Predictions
benzinga.com - March 13 at 7:37 PM
finance.yahoo.com logoImplied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options
finance.yahoo.com - March 13 at 7:37 PM
marketwatch.com logoAntidiabetic Drug Market to 2023-2028
marketwatch.com - March 10 at 3:44 AM
seekingalpha.com logoHalozyme Therapeutics: A Trailblazer, But With Lukewarm Financials
seekingalpha.com - February 26 at 8:03 AM
benzinga.com logoJP Morgan Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $52
benzinga.com - February 25 at 4:30 PM
benzinga.com logoHalozyme Therapeutics Q4 EPS $0.42 Misses $0.47 Estimate, Sales $181.50M Miss $192.05M Estimate
benzinga.com - February 23 at 4:09 PM
finance.yahoo.com logoHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
finance.yahoo.com - February 21 at 9:29 PM
247wallst.com logoBlackRock Increases Position in Halozyme Therapeutics
247wallst.com - February 15 at 10:31 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Halozyme (HALO) Stock?
finance.yahoo.com - February 10 at 1:52 PM
finance.yahoo.com logoHalozyme Appoints Barbara Duncan to its Board of Directors
finance.yahoo.com - February 6 at 9:37 AM
marketwatch.com logoHyaluronidase Market Size in 2023 Industry Demand, Industry News, Business Growth, Top Key Players Update till 2028
marketwatch.com - January 30 at 4:49 AM
finance.yahoo.com logoMultiple Reasons For the Outperformance of Halozyme Therapeutics (HALO)
finance.yahoo.com - January 23 at 8:44 AM
finance.yahoo.com logoHalozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance
finance.yahoo.com - January 12 at 2:59 PM
finance.yahoo.com logoHALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024
finance.yahoo.com - January 11 at 1:21 PM
marketwatch.com logoAntidiabetic Drug Market 2023 : Advance Technology, Latest Trend and Future Expansion by 2028
marketwatch.com - January 11 at 12:56 AM
markets.businessinsider.com logoJMP Securities Keeps Their Buy Rating on Halozyme (HALO)
markets.businessinsider.com - January 11 at 12:56 AM
finance.yahoo.com logoHalozyme Provides 2023 Financial Guidance and Outlook
finance.yahoo.com - January 10 at 7:55 PM
finance.yahoo.com logoHalo Therapeutics stock drops following weak 2023 outlook
finance.yahoo.com - January 10 at 7:55 PM
seekingalpha.com logoHalozyme Therapeutics: Chugging Along
seekingalpha.com - January 9 at 10:46 PM
finance.yahoo.com logoWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
finance.yahoo.com - January 4 at 1:13 PM
finance.yahoo.com logoInvestors in Halozyme Therapeutics (NASDAQ:HALO) have made a solid return of 219% over the past three years
finance.yahoo.com - January 3 at 10:06 AM
finance.yahoo.com logoHalozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 10:06 AM
msn.com logoHalozyme Therapeutics overweight at Morgan Stanley on Enhanze subcutaneous technology
msn.com - December 21 at 3:31 PM
finance.yahoo.com logoEpinephrine autoinjector market to grow at 8.07% Y-O-Y in 2023; Increasing prevalence of allergies will drive growth -Technavio
finance.yahoo.com - December 19 at 10:05 AM
marketwatch.com logoAntidiabetic Drug Market : Analysis, Forecast, Size, New Trends and Insights, Update, COVID-19 Impact
marketwatch.com - December 12 at 10:46 AM
markets.businessinsider.com logoWhere Halozyme Therapeutics Stands With Analysts
markets.businessinsider.com - December 8 at 3:50 PM
finance.yahoo.com logoHalozyme Therapeutics (HALO) Up 16.2% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - December 8 at 3:50 PM
markets.businessinsider.com logo5 Analysts Have This to Say About Halozyme Therapeutics
markets.businessinsider.com - December 8 at 9:18 AM
finance.yahoo.com logoEstimating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
finance.yahoo.com - December 7 at 7:23 AM
finance.yahoo.com logoLPCN: Focus on CNS Disorders
finance.yahoo.com - November 30 at 11:56 AM
finance.yahoo.com logo11 Best Diabetes Stocks To Buy Now
finance.yahoo.com - November 27 at 5:48 PM
markets.businessinsider.com logo4 Analysts Have This to Say About Halozyme Therapeutics
markets.businessinsider.com - November 22 at 6:14 PM
finance.yahoo.com logoHALO Stock: Halozyme Gets Under Your Skin To Deliver Blockbuster Drugs And Booming Growth
finance.yahoo.com - November 15 at 3:03 PM
finance.yahoo.com logoShould You Hold Halozyme Therapeutics (HALO)?
finance.yahoo.com - November 15 at 10:03 AM
finance.yahoo.com logoInterview With Quoc Tran of Tran Capital
finance.yahoo.com - November 11 at 5:57 PM
Get Halozyme Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:HALO) was last updated on 3/24/2023 by MarketBeat.com Staff